• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Government Agencies / North American / The United States / ACIP / FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance From the Advisory Committee on Immunization Practices (ACIP)

FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance From the Advisory Committee on Immunization Practices (ACIP)

March 24, 2011 By Norma Leave a Comment

MMWR. 2010;59:630-632

On October 16, 2009, the Food and Drug Administration licensed quadrivalent human papillomavirus vaccine (HPV4; Gardasil, Merck & Co. Inc.) for use in males aged 9 through 26 years for prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. HPV4 had been licensed previously for use in females aged 9 through 26 years for prevention of HPV 6, 11, 16, and 18-related outcomes (i.e., vaginal, vulvar, and cervical precancers and cancers and genital warts). The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of females at age 11 or 12 years and catch-up vaccination for females aged 13 through 26 years.1 On October 21, 2009, ACIP provided guidance that HPV4 may be given to males aged 9 through 26 years to reduce their likelihood of acquiring genital warts; ACIP does not recommend HPV4 for routine use among males. This report presents the ACIP policy statement and summarizes background data. Issues reviewed by ACIP included efficacy, immunogenicity, and safety of the HPV4 vaccine in males, epidemiology of HPV and burden of HPV-associated diseases and cancers in males, cost-effectiveness of male vaccination, and programmatic considerations.

Read entire article here.

[Note from SaneVax:  Please pay particular attention to how paragraph three is worded. The first line indicates Gardasil has been proven ‘highly effective’ in preventing genital warts in males. It is not until the end of the same paragraph that they state the ‘proven efficacy’ ranges from 62.1% to 67.2% and that median duration of follow-up was only 2.3 years.]

Related

Filed Under: ACIP, HPV Science Tagged With: genital wart prevention, HPV vaccine recommendations for males

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Gardasil: The decision I will always regret

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

uk hpv

UK HPV Vaccine Programme Errors. Aluminum Toxin

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2025 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in